GA28950: Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients with Moderate to Severe Active Ulcerative Colitis who are Refractory to or Intolerant of TNF Inhibitors

April 18, 2014
8821
Gastroenterology - Stomach
Principal Investigator: Nirmal Kaur, MD
Purpose of Research: The purpose of this research study is to determine whether etrolizumab is a safe and effective treatment for ulcerative colitis in patients with moderately to severely active ulcerative colitis who have previously been treated with a class of drugs called tumor necrosis factor (TNF) inhibitors, and your condition did not improve.
Please contact us for a full list of criteria.
Open
IBDClinicalTrials@hfhs.org
248-344-2388